Crucell N.V., a prominent biopharmaceutical company headquartered in the Netherlands, has established itself as a leader in the development of innovative vaccines and therapeutic proteins. Founded in 1993, Crucell has made significant strides in the industry, particularly in the fields of infectious diseases and monoclonal antibodies. With a strong operational presence across Europe and North America, Crucell focuses on creating unique products that leverage its proprietary technologies, such as the PER.C6® cell line. This advanced platform enables the efficient production of high-quality biopharmaceuticals, setting Crucell apart in a competitive market. Recognised for its commitment to research and development, Crucell has achieved notable milestones, including successful collaborations and partnerships that enhance its market position. The company continues to drive advancements in vaccine development, contributing to global health initiatives and improving patient outcomes.
We don't have data for Crucell N.V., but we can show you information about their parent organization instead.
View parent company